×
About 19,063 results

ALLMedicine™ B-cell Lymphoma Center

Research & Reviews  6,492 results

Histological Transformation and Clonal Relationship of Subcutaneous Marginal Zone B-Cel...
https://doi.org/10.1097/DAD.0000000000002053
The American Journal of Dermatopathology; Abbott J, Corean J et. al.

May 19th, 2022 - Histological transformation (HT) is an exceptionally uncommon and poorly understood event where a low-grade or indolent B-cell lymphoma transforms into a more aggressive entity, typically diffuse large B-cell lymphoma (DLBCL). The pathogenesis is ...

VERONICA: Randomized Phase 2 Study of Fulvestrant and Venetoclax in ER-Positive Metasta...
https://doi.org/10.1158/1078-0432.CCR-21-3811
Clinical Cancer Research : an Official Journal of the Ame... Lindeman GJ, Fernando TM et. al.

May 19th, 2022 - Despite promising activity in hematopoietic malignancies, efficacy of the B-cell lymphoma 2 (BCL) inhibitor venetoclax in solid tumors is unknown. We report the prespecified VERONICA primary results, a randomized phase 2 clinical trial evaluating ...

Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion an...
https://doi.org/10.1158/1078-0432.CCR-22-0164
Clinical Cancer Research : an Official Journal of the Ame... Monfrini C, Stella F et. al.

May 19th, 2022 - In clinical trials, the expansion and persistence of CAR-T cells correlate with therapeutic efficacy. However, properties of CAR-T cells that enable their in vivo proliferation have still to be consistently defined and the role of CAR-T bag conten...

THE ANTIBODY-DRUG CONJUGATE LONCASTUXIMAB TESIRINE FOR THE TREATMENT OF DIFFUSE LARGE B...
https://doi.org/10.1182/blood.2021014663
Blood Calabretta E, Hamadani M et. al.

May 18th, 2022 - Diffuse large B-cell lymphoma (DLBCL) is a heterogenous subtype of non-Hodgkin lymphoma. Relapsed/refractory disease represents remains an unmet medical need, despite the introduction of novel cellular and targeted therapies. Loncastuximab tesirin...

CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to...
https://doi.org/10.1111/cas.15402
Cancer Science; Dong L, Huang J et. al.

May 18th, 2022 - Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy with a high relapse rate of up to 40%. The prognosis of the disease remains improvement and requires a understanding of its molecular mechanism. We investigated the mecha...

see more →

Guidelines  11 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Gu...
https://doi.org/10.6004/jnccn.2020.0036
Journal of the National Comprehensive Cancer Network : JN... Davies K, Barth M et. al.

Aug 7th, 2020 - Pediatric aggressive mature B-cell lymphomas are the most common types of non-Hodgkin lymphoma in children, and they include Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL). These diseases are highly aggressive but curable, the tre...

The management of primary mediastinal B-cell lymphoma: a British Society for Haematolog...
https://doi.org/10.1111/bjh.15731
British Journal of Haematology; Cwynarski K, Marzolini MAV et. al.

Jan 5th, 2019 - The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper.|2019|Cwynarski K,Marzolini MAV,Barrington SF,Follows G,Illidge T,|adverse effects,therapeutic use,chemically induced,diagnostic imaging,t...

Guidelines for the diagnosis and management of primary central nervous system diffuse l...
https://doi.org/10.1111/bjh.15661
British Journal of Haematology; Fox CP, Phillips EH et. al.

Nov 24th, 2018 - Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma.|2018|Fox CP,Phillips EH,Smith J,Linton K,Gallop-Evans E,|diagnosis,therapy,diagnosis,therapy,

Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lym...
https://doi.org/10.1016/j.ijrobp.2017.12.005
International Journal of Radiation Oncology, Biology, Phy... Ng AK, Yahalom J et. al.

Feb 8th, 2018 - Approximately 30% to 40% of patients with diffuse large B-cell lymphoma (DLBCL) will have either primary refractory disease or relapse after chemotherapy. In transplant-eligible patients, those with disease sensitive to salvage chemotherapy will s...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  269 results

Genome Expression in Lymphoma, Leukemia and Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT00339963

May 13th, 2022 - Current diagnosis of the lymphoid malignancies relies upon the morphological appearance of the cancer cells supplemented by a few molecular markers. Within a diagnostic category, the clinical courses and responses of patients to therapy are variab...

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT04933617

May 13th, 2022 - Background: Burkitt Lymphoma (BL) is a highly aggressive B cell lymphoma that often involves the bone marrow and central nervous system (CNS) Frontline therapy cures 80-85% of adults with BL but patients with CNS involvement or those who relapse a...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT03223610

May 13th, 2022 - Background: Combination chemotherapy with Rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy but indolent lymphomas and ...

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03255018

May 13th, 2022 - Background: Gray-zone lymphomas (GZL) are rare, aggressive lymphomas that share clinical and biological features of diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma Standard upfront therapy for GZL is dose-intensive chemotherapy, though ...

Treatment and Natural History Study of Lymphomatoid Granulomatosis
https://clinicaltrials.gov/ct2/show/NCT00001379

May 13th, 2022 - BACKGROUND: Lymphomatoid granulomatosis (LYG) is an angiocentric destructive proliferation of lymphoid cells predominantly involving the lungs, skin, kidneys, and central nervous system. It is divided into three grades, depending on the degree of ...

see more →

News  840 results

‘Agony of choice’ for clinicians treating leukemia
https://www.mdedge.com/hematology-oncology/article/254465/cll/agony-choice-clinicians-treating-leukemia
Nancy A. Melville

May 10th, 2022 - With an abundance of targeted therapies transforming the treatment landscape for chronic lymphocytic leukemia (CLL), picking the optimal drug or drug sequence for the right situation can be a challenge, but emerging data is helping guide clinician.

FDA Lifts Partial Clinical Hold Placed on Studies Evaluating Magrolimab in MDS and AML
https://www.onclive.com/view/fda-lifts-partial-clinical-hold-placed-on-studies-evaluating-magrolimab-in-mds-and-aml

May 7th, 2022 - The FDA has lifted a partial clinical hold that had been placed on studies examining magrolimab in combination with azacitidine following a review of comprehensive safety data collected from each trial, according to an announcement from Gilead Sci...

Second-Line Axi-Cel Offers a “Practice-Changing” Indication for LBCL
https://www.onclive.com/view/second-line-axi-cel-offers-a-practice-changing-indication-for-lbcl

May 3rd, 2022 - Based on data from the phase 3 ZUMA-7 trial (NCT03391466), the FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the second-line treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimm...

FDA Approves Axicabtagene Ciloleucel for Second-Line LBCL
https://www.onclive.com/view/fda-approves-axicabtagene-ciloleucel-for-second-line-lbcl

Apr 28th, 2022 - The FDA has approved axicabtagene ciloleucel (axi-cel; Yescarta) for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.1 Th...

Liso-cel Continues to Demonstrate Clinical Responses in Relapsed/Refractory LBCL at 2-Year Follow-Up
https://www.onclive.com/view/liso-cel-continues-to-demonstrate-clinical-responses-in-relapsed-refractory-lbcl-at-2-year-follow-up

Apr 25th, 2022 - The utilization of lisocabtagene maraleucel (liso-cel; Breyanzi) in patients with relapsed/refractory large B-cell lymphomas (LBCL) produced durable outcomes at a 2 years follow-up, according to results from the phase 1 TRANSCEND NHL 001 trial (NC...

see more →

Patient Education  1 results see all →